期刊文献+

火焰原子吸收光谱法快速测定西酞普兰中的微量铜 被引量:1

Rapid Determination of Trace Copper in Citalopram by Flame Atomic Absorption Spectrometry
下载PDF
导出
摘要 研究了硝酸-乙醇-水介质中,用空气-乙炔火焰原子吸收光谱法测定西酞普兰中微量铜的方法。结果表明,在最佳实验条件下,铜的线性范围为0.01—0.50μg/mL,相关系数(r)0.9996,检出限0.0052μg/mL。用本方法测定西酞普兰中的铜,加标回收率97%—104%。 A method for determination of trace copper in citalopram spectrometry was developed in a medium of nitric acid-etha by air-acetylene flame atomic absorption nol-water. Experimental results showed that the linear range of copper was 0. 01-0. 50μg/mL and the correlation coefficient (r) was 0. 9996 with a detection limit of 0. 0052μg/mL. The method has been used for the determination of copper in the citalopram that the recovery was 97%-104%.
机构地区 台州学院化学系
出处 《光谱实验室》 CAS CSCD 2005年第6期1319-1321,共3页 Chinese Journal of Spectroscopy Laboratory
基金 浙江省自然科学基金(M203115)资助
关键词 西酞普兰 火焰原子吸收光谱法 Citalopram,Flame Atomic Absorption Spectrometry,Copper.
  • 相关文献

参考文献6

二级参考文献61

  • 1[1]Mendels J, Kiev A, Fabre L. Double-blind comparison of citalopram and placebo in depressed outpatients with melancholia. Depress Anxiety,1999,9(2) :54~60.
  • 2[2]Leinonen E, Skarstein J, Behnke K, et al. Efficacy and tolerability of mitazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant study group. Int Clin Psychopharmacol, 1999,14(6) :37~329.
  • 3[3]Ekselius L,Von Knorring L,Eberhard G. A double-blind multicenter trial comparing sertraline and citalopram in patients with major depression treated in general practice. Int Clin Psyc hopharmacol, 1997,12 (6): 31~323.
  • 4[4]Patris M, Bouchard J, Bougerol T, et al. Citalopram versus fluoxetine: a double-blind,controlled,muticentre,phase Ⅲ trial in patients with unipolar major depression treated in general practice. Int Clin Psychopharmacology, 1996,11 (2): 36~129.
  • 5[5]Rosenberg C,Damsbo N,Fuglun E,et al. Citaloprarn and imipramine in the treatment of depressive patients in general practice. A nordic multicentre clinical study. Int Clin Psychopharmacol, 1994, 9 (Suppl 1): 8~41.
  • 6[6]Robert P, Montgomery S. A 24-week study of 20mg citalopram, 40mg citalopram,and placebo in the prevention of relapse of major depression. Int Clin Psychopharmacol, 1993,8 (3): 8~181.
  • 7[7]Montgomery S, Rasmusen J, Tanghoj P. Citalopram in doses of 20~60mg is effective in depression relapse prevention: a placebo-controlled 6 month study. Int Clin Psychopharmacol, 1995,10(Suppl 1 ) :29~35.
  • 8[8]Haffmans P, Timmerman L, Hoogduin C. Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatients: a doubleblind, multicentre study. The LUCIFER Group. Int Clin Psychopharmacol, 1996,11 (3) :64~157.
  • 9[9]Landen M,Bjorling G. Agren H, et al. A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression. Journal of Clinical Psychiatry,1998,57(12) :8~664.
  • 10[10]Baumann P,Nil R,Soue A,et al.A double-blind,placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients. A clinical, pharmacokinetic , and pharmacogenetic investigation. Journal of Clinical Psychopharrnacology, 1996, 16 (4): 4~

共引文献39

同被引文献647

引证文献1

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部